<DOC>
	<DOCNO>NCT00874796</DOCNO>
	<brief_summary>This Phase 2b , randomize , double-blind , parallel-group , placebo-controlled , multicenter study investigate safety , tolerability efficacy two oral dos GS-9450 adult chronic Hepatitis C Virus ( HCV ) . Approximately 240 subject 18-65 year age meet study entry criterion randomize ( word , select random , like flip coin ) one three treatment group ( 80 subject per treatment group ) follow : GS-9450 10 mg daily , GS-9450 40 mg daily , match placebo daily . Following randomization , subject return within seven business day Baseline ( Day 1 ) visit , time study medication dispense subject enter 26 week treatment phase . During treatment phase , subject receive study drug daily 24 week taper study drug follow 2 week receive study drug every day one week every 3 day one week . Following completion treatment phase , subject enter 4-week off-treatment follow-up phase .</brief_summary>
	<brief_title>Efficacy Safety Study GS-9450 Treatment 6 Months Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Adult subject , age 1865 Chronic HCV infection , define document HCV infection ( antibody RNA positivity ) least 6 month prior Baseline ( Day 1 ) HCV viremia screen Screening Knodell necroinflammatory score &gt; = 3 base liver biopsy evaluation ( determined local pathologist ) conduct anytime 45day screening period ALT &gt; upper limit normal range ( ULN ) &lt; 10 X ULN screen visit Previously fail pegylated interferonbased HCV therapy combination ribavirin therapy , unable tolerate contraindication receive interferon ribavirin therapy BMI 19 36 kg/m2 ( inclusive ) Creatinine clearance &gt; = 70 mL/min absolute neutrophil count &gt; = 1000/mm3 Hemoglobin &gt; 10 g/dL Have clinical laboratory evidence hepatic decompensation Decompensated liver disease ChildPugh grade B C cirrhosis Evidence hepatocellular carcinoma Positive urine drug screen cocaine amphetamine Infection HCV genotype 3 Coinfection hepatitis B virus human immunodeficiency virus Pancreatitis Recent significant infection symptom infection Autoimmune disorder Any history seizure Is public transportation operator ( pilot airplane ship ; air traffic controller ; bus , train subway driver ) operate heavy construction machinery Transplantation History malignancy Current excessive alcohol ingestion , average &gt; 3 drinks/day female &gt; 4 drinks/day male History current binge drinking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>apoptosis</keyword>
	<keyword>liver inflammation</keyword>
	<keyword>hepatitis C</keyword>
</DOC>